Synopsis: The PERSEVERE trial evaluated the AMDS Hybrid Prosthesis, a novel self-expanding stent, for patients with acute DeBakey Type I (ADTI) aortic dissection and malperfusion. The device demonstrated reduced major adverse events (MAEs), no distal anastomotic new entry (DANE) tears at 30 days, and favorable postoperative aortic remodeling.
Summary: Current guidelines recommend urgent hemiarch repair for patients with acute DeBakey Type I (ADTI) aortic dissection. However, malperfusion and poor distal aortic remodeling remain significant contributors to morbidity and mortality in this population. The PERSEVERE trial investigated the AMDS Hybrid Prosthesis, a novel self-expanding stent designed for antegrade deployment into the arch and descending thoracic aorta during open repair. This study examined outcomes in patients with ADTI and malperfusion treated with the device.
The trial was a prospective, single arm, nonblinded study conducted at 26 sites. Eligible patients were between 18–80 years old with clinical or radiographic evidence of malperfusion. Exclusion criteria included life expectancy < 2 years, coronary malperfusion, circulatory shock, connective tissue disorders, and primary entry tears in the arch or distal aorta. Two co-primary endpoints were evaluated: the incidence of 30-day major adverse events (MAEs)—a composite of all-cause mortality, new disabling stroke, renal failure requiring dialysis, and myocardial infarction—and the occurrence of any distal anastomotic new entry (DANE) tears at 30 days. Results were compared to a reference cohort of similar patients from five previous studies, with predefined performance goals of 58% for MAEs and 45% for DANE. Secondary endpoints included technical success, aortic remodeling parameters, and unanticipated aortic reoperations.
A total of 93 patients were enrolled, with an average age of 59 years. Most patients were male (79%) and white (60%), and 82% presented with clinical malperfusion. Cerebral perfusion was utilized in 95% of cases (46% antegrade, 48% retrograde). Concomitant cardiac operations were common (84%), including aortic root interventions (39%), aortic valve resuspensions (37%), other valve interventions (23%), and coronary artery bypass grafting (5%).
The incidence of 30-day MAEs was 27% (reference cohort: 58%), including 10% 30-day mortality, 11% new disabling stroke, 19% new renal failure, and no myocardial infarctions. No DANE tears were observed at 30 days (reference cohort: 45%). Both co-primary endpoints met the predefined goals. Technical success was achieved in 99% of patients. Postoperative aortic remodeling demonstrated stable or decreased total aortic diameters in zones 1 (94%), 2 (89%), and 3 (81%). Corresponding reductions in false lumen diameter were observed in zones 1 (-11.6 ± 6.4 mm), 2 (-10.8 ± 5.5 mm), and 3 (-3.5 ± 6.0 mm).
In conclusion, early results from the PERSEVERE trial demonstrated significant reductions in MAEs and no incidence of DANE in patients with ADTI and malperfusion treated with the AMDS Hybrid Prosthesis. Secondary outcomes showed encouraging postoperative aortic remodeling. The device’s simple deployment technique and minimal additional circulatory arrest time make it a promising, safe, and effective option for the treatment of ADTI dissection.
The PERSEVERE trial, while demonstrating promising early results, is limited by its single-arm design, small sample size, and short term follow up. The lack of long-term data and a control group restricts the ability to draw definitive conclusions about the device's effectiveness relative to standard treatments.
Bottom Line:
The AMDS Hybrid Prosthesis demonstrates reduced major adverse events, no distal new entry tears, and favorable aortic remodeling in patients with ADTI dissection and malperfusion. This novel device offers a feasible and effective solution to improve outcomes in open aortic repair.